Track every
FDA Priority Review Voucher Program.

A comprehensive source for PRV issuances, sales and redemptions. Designed for research, analytics and market intelligence.

Thank you!
Oops! Something went wrong while submitting your email.
Dashboard showing priority review voucher transactions with scatterplot, details popup, transaction list, and status.
Market Overview
Total Issued
-
Redeemed
-
Last Sale
-
0% vs prev sale
Background

What are FDA Priority Review Vouchers?

The FDA Priority Review Voucher programs incentivize drug development by rewarding companies that bring certain qualifying treatments to market.

RPD

Rare Pediatric Disease

Awarded for treatments of serious or life-threatening rare diseases that primarily affect children under 18.

TD

Tropical Disease

Awarded for prevention or treatment of certain tropical diseases that have had limited historic investment.

CNPV

Commissioner's National Priority Voucher

A pilot program rewarding treatments aligned with US national health priorities identified by FDA.

MTMC

Material Threat Medical Countermeasure

Awarded for prevention or treatment against high-risk threats such as chemical, biological, radiological, or nuclear agents.

NDA/BLA

NDA/BLA

New Drug Application (NDA) / Biologics License Application (BLA)

Supplemental

Supplemental NDA/BLA

Supplemental New Drug Application (NDA) / Biologics License Application (BLA)

Priority vouchers issued

Vouchers issued across all FDA programmes

TD
TD
Tropical Disease
Awarded for prevention or treatment of certain tropical diseases that have had limited historic investment.
RPD
RPD
Rare Pediatric Disease
Awarded for treatments of serious or life-threatening rare diseases that primarily affect children under 18.
MTMC
MTMC
Material Threat Medical Countermeasure
Awarded for prevention or treatment against high-risk threats such as chemical, biological, radiological, or nuclear agents.
CNPV
CNPV
Commissioner's National Priority Voucher
A pilot program rewarding treatments aligned with US national health priorities identified by FDA.

Voucher type issued

CNPV
CNPV
Commissioner's National Priority Voucher
A pilot program rewarding treatments aligned with US national health priorities identified by FDA.
MTMC
MTMC
Material Threat Medical Countermeasure
Awarded for prevention or treatment against high-risk threats such as chemical, biological, radiological, or nuclear agents.
RPD
RPD
Rare Pediatric Disease
Awarded for treatments of serious or life-threatening rare diseases that primarily affect children under 18.
TD
TD
Tropical Disease
Awarded for prevention or treatment of certain tropical diseases that have had limited historic investment.

RPD, TD, or MTMC priority review vouchers

May be redeemed to obtain priority review for a product application that would otherwise not receive priority review. PRVs can also be sold or transferred between different companies.

Transferable · No expiry

Commissioner's National Priority Voucher

Reduces the timelines for FDA review from ~10-12 months to 1-2 months. These vouchers cannot be sold or transferred to another company and must be redeemed within 2 years.

Non-transferable · Must redeem within 2 years

Vouchers issued <12m

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Issued
Company
Product
Voucher
Status
May 2026
Partner Therapeutics, Inc.
Bizengri
CNPV
Redeemed
Apr 2026
Transcend ⁠Therapeutics
methylone
CNPV
Unused
Apr 2026
Usona Institute
psilocybin
CNPV
Unused
Apr 2026
Compass Pathways
psilocybin
CNPV
Unused
Apr 2026
Regeneron
Otarmeni
RPD
Unknown
Mar 2026
Rocket Pharmaceuticals, Inc.
Kresladi
RPD
Sold
Mar 2026
Denali Therapeutics Inc.
Avlayah
RPD
Unknown
Feb 2026
Sun Pharma
Sezaby
RPD
Sold
Feb 2026
Immedica Pharma AB
Loargys
RPD
Sold
Feb 2026
Ascendis Pharma
Yuviwel
RPD
Sold
Jan 2026
Sentynl Therapeutics, Inc.
Zycubo
RPD
Sold
Dec 2025
Merck & Co., Inc.
sacituzumab tirumotecan
CNPV
Unused
Dec 2025
Merck & Co., Inc.
enlicitide
CNPV
Unused
Dec 2025
Johnson & Johnson
Tecvayli
CNPV
Redeemed
Dec 2025
Fondazione Telethon ETS
Waskyra
RPD
Unknown
Nov 2025
GSK
Jemperli
CNPV
Unused
Nov 2025
Novo Nordisk Inc.
Wegovy
CNPV
Redeemed
Nov 2025
Eli Lilly and Company
orforglipron
CNPV
Redeemed
Nov 2025
Johnson & Johnson
Sirturo
CNPV
Unused
Nov 2025
Vertex Pharmaceuticals
Casgevy
CNPV
Redeemed
Nov 2025
Boehringer Ingelheim
Hernexeos
CNPV
Redeemed
Nov 2025
UCB
Kygevvi
RPD
Unknown
Oct 2025
Regeneron
DB-OTO
CNPV
Redeemed
Oct 2025
Phlow
ketamine
CNPV
Unused
Oct 2025
Revolution Medicines
daraxonrasib
CNPV
Unused
Oct 2025
Dompé
Oxervate
CNPV
Unused
Oct 2025
Achieve Life Sciences
cytisinicline
CNPV
Unused
Oct 2025
EMD Serono
Pergoveris
CNPV
Redeemed
Oct 2025
Sanofi
Tzield
CNPV
Redeemed
Oct 2025
Disc Medicine
bitopertin
CNPV
Redeemed
Oct 2025
USAntibiotics
Augmentin XR
CNPV
Redeemed
Sep 2025
Stealth BioTherapeutics
Forzinity
RPD
Unknown
Aug 2025
Jazz Pharmaceuticals PLC
Modeyso
RPD
Sold
Approved
Company
Product
Voucher
Status
November 2025
Boehringer Ingelheim
Hernexeos
CNPV
Redeemed
November 2025
UCB
Kygevvi
RPD
Unknown
October 2025
Regeneron
DB-OTO
CNPV
Redeemed
October 2025
Phlow
ketamine
CNPV
Unused
October 2025
Revolution Medicines
daraxonrasib
CNPV
Unused

Redeemed - voucher was used by the original company the voucher was awarded to.

Sold - voucher was sold onwards, vouchers may have been subsequently redeemed.

Unknown - no public disclosure relating to this specific voucher.

Unused - voucher not redeemed.

Commissioner's National Priority Voucher (CNPV) tracker

0
results
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Company
Product
Indication
Voucher
FDA Filing / Approval
Pergoveris
Infertility
Redeemed
Initiated filing submission
Tzield
Stage 3 Type 1 diabetes
Redeemed
Decision delayed
cytisinicline
Nicotine vaping / e-cig addiction
Unused
Est. filing 2027
DB-OTO
Deafness (OTOF-related)
Redeemed
Approved Apr 23rd 2026
Oxervate
Blindness (NAION)
Unused
Unknown filing date
daraxonrasib
Pancreatic cancer (PDAC)
Unused
Est. filing 2026/2027
bitopertin
Erythropoietic Protoporphyria
Redeemed
Received CRL Feb 13 2026
ketamine
General anesthesia
Unused
Unknown filing date
Augmentin XR
Bacterial infections
Redeemed
Approved Dec 10 2025
Hernexeos
1L HER2 advanced NSCLC
Redeemed
Approved Feb 26 2026
Sirturo
Pediatric multi-drug resistant TB
Unused
Est. filing 2027
Jemperli
dMMR/MSI-H advanced rectal cancer
Unused
Est. filing 2026/2027
Casgevy
Pediatric severe sickle cell disease
Redeemed
Filing H1 2026
orforglipron
Obesity
Redeemed
Approved Mar 5th 2026
Wegovy
Obesity (7.2mg dose)
Redeemed
Approved Mar 20th 2026
Tecvayli + Darzalex
for r/r multiple myeloma
Redeemed
Approved Mar 5 2026
enlicitide
LDL-C reduction
Unused
Filing H1 2026
sacituzumab tirumotecan
Triple-negative breast cancer
Unused
Unknown filing date
psilocybin
Treatment-resistant depression
Unused
Est filing Q4 2026
psilocybin
Major depressive disorder
Unused
Unknown filing date
methylone
Post-Traumatic Stress Disorder
Unused
Unknown filing date
Bizengri
NRG1 cholangiocarcinoma
Redeemed
Approved May 8th 2026
Company
Product
Indication
Voucher
FDI Filling / Approval date
Hernexeos
1L HER2 advanced NSCLC
Redeemed
Approved Feb 26 2026
bitopertin
Erythropoietic Protoporphyria
Redeemed
Received CRL Feb 13 2026
Jemperli
dMMR/MSI-H advanced rectal cancer
Unused
Est. filing 2026/2027
Augmentin XR
Bacterial infections
Redeemed
Approved Dec 10 2025
Sirturo
Pediatric multi-drug resistant TB
Unused
Est. filing 2027

PRVs sold over time (USD)

Only PRV transactions with a publicly disclosed price is shown. Where an exact date is not disclosed, the data point is marked at the last quarter of the reported time period. E.g if a sale/acquisition occurred in 2019 but no specified date given, this has been attributed to 2019 Q4.

Priority vouchers redeemed

Vouchers redeemed by year

Supplemental NDA/BLA
Supplemental
Supplemental NDA / BLA
Voucher redeemed on a supplemental application — typically a new indication, formulation, or patient population for an already-approved drug.
NDA/BLA
NDA / BLA
New Drug or Biologics Application
Voucher redeemed on a new marketing application — either a New Drug Application (NDA) or Biologics License Application (BLA).

Redeemed by application type

NDA/BLA
NDA / BLA
New Drug or Biologics Application
Voucher redeemed on a new marketing application — either a New Drug Application (NDA) or Biologics License Application (BLA).
Supplemental NDA/BLA
Supplemental
Supplemental NDA / BLA
Voucher redeemed on a supplemental application — typically a new indication, formulation, or patient population for an already-approved drug.

CNPVs redeemed

Redeemed
Unused

A priority review voucher was redeemed in Q4 2025 but it is currently unknown if this was redeemed for a new or supplementary application. This voucher is not accounted for in the chart above.

Redeemed by disease area

A priority review voucher was redeemed in Q4 2025 but it is currently unknown which product/indication this was redeemed for. This voucher is not accounted for in the chart above.

PRVWatch Pro

Full breakdown by therapeutic and disease area — available with PRVWatch Pro.

Stacked bar chart showing multiple categories over 20 data points with varying values in four colors.

PRVWatch Pro

Access the full dataset, raw tables, and advanced charts.

Heading

Heading 1

Heading 2

Heading 3

Heading 4

Heading 5
Heading 6

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Block quote

Ordered list

  1. Item 1
  2. Item 2
  3. Item 3

Unordered list

  • Item A
  • Item B
  • Item C

Text link

Bold text

Emphasis

Superscript

Subscript

Track every
FDA Priority Review Voucher Program.

Stay updated
Thank you!
Oops! Something went wrong while submitting your email.

This webpage has been compiled from manually reviewing thousands of documents from the U.S. Securities and Exchange Commission (SEC), U.S. Food and Drug Administrations (FDA), Federal Register, press releases and financial records. The information on this page has been compiled from publicly available sources only and does not include any undisclosed PRV issuance's, transactions or redemptions.

Stay in the loop

News, analysis, and insights from the world of Priority Review Vouchers.

Thank you!
Oops! Something went wrong while submitting your email.